this post was submitted on 19 Oct 2023
186 points (98.4% liked)

science

21320 readers
390 users here now

A community to post scientific articles, news, and civil discussion.

rule #1: be kind

founded 2 years ago
MODERATORS
 

The antiviral drug ensitrelvir, which shortens sensory problems, is one of the few COVID-19 drugs available to people not at high risk of grave illness.

you are viewing a single comment's thread
view the rest of the comments
[–] MrZee@lemm.ee 22 points 2 years ago (1 children)

From the article:

At the start of the study, 20% of participants reported some level of smell or taste loss. After the third day of treatment, the proportion of participants reporting such symptoms in the ensitrelvir groups started dropping more sharply than did the proportion in the placebo group. At day seven, the percentage of participants with smell or taste loss was 39% lower in the group taking 250-milligram pills than in the placebo group. Three weeks after treatment began, all groups reported similar symptom scores. [emphasis added]

Unless I’m misreading this, they saw some notable reduction in symptoms at 1 week, but the benefit had faded away by the time they hit three weeks. This seems to imply that the drug doesn’t provide any reduction in long-term loss of smell (or at least, such a benefit was not shown in this particular trial).

[–] lupec@lemm.ee 2 points 2 years ago

Yeah, that's how I'm reading it as well